

Michael A Eller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9050826/publications.pdf>

Version: 2024-02-01

83
papers

3,856
citations

147801

31
h-index

133252

59
g-index

87
all docs

87
docs citations

87
times ranked

7187
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-Cell Profiling of Latently SIV-Infected CD4 ⁺ T Cells Directly <i>Ex Vivo</i> to Reveal Host Factors Supporting Reservoir Persistence. <i>Microbiology Spectrum</i> , 2022, 10, e0060422.	3.0	1
2	Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. <i>IScience</i> , 2021, 24, 102047.	4.1	16
3	Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors. <i>Frontiers in Immunology</i> , 2021, 12, 682120.	4.8	9
4	Increased Inflammation and Liver Disease in HIV/HBV-coinfected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, 310-313.	2.1	4
5	Preferential and persistent impact of acute HIV-1 infection on CD4 ⁺ iNKT cells in colonic mucosa. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	2
6	Cerebrospinal fluid CD4 ⁺ T cell infection in humans and macaques during acute HIV-1 and SHIV infection. <i>PLoS Pathogens</i> , 2021, 17, e1010105.	4.7	9
7	Monocyte activation, HIV, and cognitive performance in East Africa. <i>Journal of NeuroVirology</i> , 2020, 26, 52-59.	2.1	9
8	Activated PD-1 ⁺ CD4 ⁺ T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ART. <i>Aids</i> , 2020, 34, 197-202.	2.2	6
9	Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. <i>PLoS Pathogens</i> , 2020, 16, e1008764.	4.7	37
10	Longitudinal Analysis of Peripheral and Colonic CD161 ⁺ CD4 ⁺ T Cell Dysfunction in Acute HIV-1 Infection and Effects of Early Treatment Initiation. <i>Viruses</i> , 2020, 12, 1426.	3.3	3
11	B Cell Compartmentalization in Blood and Cerebrospinal Fluid of HIV-Infected Ugandans with Cryptococcal Meningitis. <i>Infection and Immunity</i> , 2020, 88, .	2.2	9
12	A de novo approach to inferring within-host fitness effects during untreated HIV-1 infection. <i>PLoS Pathogens</i> , 2020, 16, e1008171.	4.7	4
13	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. <i>Nature Medicine</i> , 2020, 26, 498-501.	30.7	43
14	Monocyte and CD4 ⁺ T-cell antiviral and innate responses associated with HIV-1 inflammation and cognitive impairment. <i>Aids</i> , 2020, 34, 1289-1301.	2.2	8
15	Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. <i>Lancet HIV</i> , 2020, 7, e238-e248.	4.7	33
16	Impact of the expression system on the immune responses to self-assembling protein nanoparticles (SAPNs) displaying HIV-1 V1V2 loop. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 29, 102255.	3.3	5
17	Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection. <i>Nature Communications</i> , 2020, 11, 272.	12.8	38
18	Preferential Infection of $\hat{1}\pm 4\hat{1}^{27}$ + Memory CD4 ⁺ T Cells During Early Acute Human Immunodeficiency Virus Type 1 Infection. <i>Clinical Infectious Diseases</i> , 2020, 71, e735-e743.	5.8	14

#	ARTICLE	IF	CITATIONS
19	RV144 HIV-1 vaccination impacts post-infection antibody responses. <i>PLoS Pathogens</i> , 2020, 16, e1009101.	4.7	13
20	A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	26
21	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2019, 6, e297-e306.	4.7	73
22	Expansion of Stem Cell-Like CD4 ⁺ Memory T Cells during Acute HIV-1 Infection Is Linked to Rapid Disease Progression. <i>Journal of Virology</i> , 2019, 93, .	3.4	11
23	Terminal Effector CD8 T Cells Defined by an IKZF2+IL-7R ^{hi} Transcriptional Signature Express FcÎ³RIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Immunology</i> , 2019, 203, 2210-2221.	0.8	23
24	Biomarkers of Inflammation Correlate With Clinical Scoring Indices in Human Immunodeficiency Virus-Infected Kenyans. <i>Journal of Infectious Diseases</i> , 2019, 219, 284-294.	4.0	7
25	OMIP-046: Characterization of invariant T cell subset activation in humans. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 499-503.	1.5	7
26	Transcriptomic signatures of NK cells suggest impaired responsiveness in HIV-1 infection and increased activity post-vaccination. <i>Nature Communications</i> , 2018, 9, 1212.	12.8	44
27	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. <i>Journal of Infectious Diseases</i> , 2018, 218, 633-644.	4.0	35
28	The CD4 ^{hi} CD8 ^{hi} MAIT cell subpopulation is a functionally distinct subset developmentally related to the main CD8 ⁺ MAIT cell pool. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11513-E11522.	7.1	147
29	Single-cell Quantitation of mRNA and Surface Protein Expression in Simian Immunodeficiency Virus-infected CD4 ⁺ T Cells Isolated from Rhesus macaques. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	3
30	Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans. <i>Journal of Virology</i> , 2018, 92, .	3.4	7
31	Limited immune surveillance in lymphoid tissue by cytolytic CD4 ⁺ T cells during health and HIV disease. <i>PLoS Pathogens</i> , 2018, 14, e1006973.	4.7	30
32	Evolution of HIV-1 within untreated individuals and at the population scale in Uganda. <i>PLoS Pathogens</i> , 2018, 14, e1007167.	4.7	27
33	Liposome-Encapsulated Human Immunodeficiency Virus-1 gp120 Induces Potent V1V2-Specific Antibodies in Humans. <i>Journal of Infectious Diseases</i> , 2018, 218, 1541-1550.	4.0	22
34	A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity. <i>Journal of Immunological Methods</i> , 2018, 462, 74-82.	1.4	19
35	Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size. <i>JCI Insight</i> , 2018, 3, .	5.0	32
36	Ontogeny of CD4 ⁺ T Lymphocytes with Phenotypic Susceptibility to HIV-1 during Exclusive and Non-Exclusive Breastfeeding in HIV-1-exposed Ugandan Infants. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw553.	4.0	3

#	ARTICLE	IF	CITATIONS
37	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2017, 215, 1255-1263.	4.0	57
38	Preservation of Peripheral T Follicular Helper Cell Function in HIV Controllers. <i>Journal of Virology</i> , 2017, 91, .	3.4	32
39	Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost. <i>Journal of Infectious Diseases</i> , 2017, 216, 1080-1090.	4.0	23
40	Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection. <i>Journal of Virology</i> , 2017, 91, .	3.4	39
41	Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. <i>PLoS Pathogens</i> , 2017, 13, e1006510.	4.7	63
42	T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response. <i>JCI Insight</i> , 2017, 2, .	5.0	164
43	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 15-20.	2.1	12
44	Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. <i>New England Journal of Medicine</i> , 2016, 374, 2120-2130.	27.0	229
45	Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection. <i>Journal of Virology</i> , 2016, 90, 4005-4016.	3.4	25
46	Circulating HIV-Specific Interleukin-21+CD4+ T Cells Represent Peripheral Tfh Cells with Antigen-Dependent Helper Functions. <i>Immunity</i> , 2016, 44, 167-178.	14.3	104
47	Sex and Urbanicity Contribute to Variation in Lymphocyte Distribution across Ugandan Populations. <i>PLoS ONE</i> , 2016, 11, e0146196.	2.5	5
48	Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005805.	4.7	36
49	A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda. <i>ELife</i> , 2016, 5, .	6.0	46
50	<sc>OMIP</sc> 27: Functional analysis of human natural killer cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2015, 87, 803-805.	1.5	13
51	HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation Levels. <i>Journal of Infectious Diseases</i> , 2015, 211, 1574-1584.	4.0	17
52	Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. <i>Lancet Infectious Diseases</i> , 2015, 15, 905-912.	9.1	193
53	Cooperativity of HIV-Specific Cytolytic CD4 T Cells and CD8 T Cells in Control of HIV Viremia. <i>Journal of Virology</i> , 2015, 89, 7494-7505.	3.4	70
54	Cellular Immune Activation in Cerebrospinal Fluid From Ugandans With Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome. <i>Journal of Infectious Diseases</i> , 2015, 211, 1597-1606.	4.0	55

#	ARTICLE	IF	CITATIONS
55	Cryptic Multiple HIV-1 Infection Revealed by Early, Frequent, and Deep Sampling during Acute Infection. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A58-A58.	1.1	2
56	Impaired natural killer cell responses are associated with loss of the highly activated NKG2A+CD57+CD56dim subset in HIV-1 subtype D infection in Uganda. <i>Aids</i> , 2014, 28, 1273-1278.	2.2	15
57	Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 13439-13444.	7.1	49
58	Differential Loss of Invariant Natural Killer T Cells and FoxP3+ Regulatory T Cells in HIV-1 Subtype A and Subtype D Infections. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 289-293.	2.1	4
59	Detection of HIV-1 Neutralizing Antibodies in a Human CD4+/CXCR4+/CCR5+ T-Lymphoblastoid Cell Assay System. <i>PLoS ONE</i> , 2013, 8, e77756.	2.5	32
60	Platelets and Erythrocyte-Bound Platelets Bind Infectious HIV-1 in Plasma of Chronically Infected Patients. <i>PLoS ONE</i> , 2013, 8, e81002.	2.5	15
61	Short Communication: Colony-Forming Hematopoietic Progenitor Cells Are Not Preferentially Infected by HIV Type 1 Subtypes A and Din Vivo. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1119-1123.	1.1	1
62	Single-Cell Level Response of HIV-Specific and Cytomegalovirus-Specific CD4 T Cells Correlate With Viral Control in Chronic HIV-1 Subtype A Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 9-18.	2.1	5
63	OMIP007: Phenotypic analysis of human natural killer cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 447-449.	1.5	33
64	A Double-Blind Randomized Phase I Clinical Trial Targeting ALVAC-HIV Vaccine to Human Dendritic Cells. <i>PLoS ONE</i> , 2011, 6, e24254.	2.5	8
65	Human Immunodeficiency Virus Type 1 Infection Is Associated with Increased NK Cell Polyfunctionality and Higher Levels of KIR3DL1 ⁺ NK Cells in Ugandans Carrying the HLA-B Bw4 Motif. <i>Journal of Virology</i> , 2011, 85, 4802-4811.	3.4	14
66	Innate and Adaptive Immune Responses Both Contribute to Pathological CD4 T Cell Activation in HIV-1 Infected Ugandans. <i>PLoS ONE</i> , 2011, 6, e18779.	2.5	36
67	B Cell Depletion in HIV-1 Subtype A Infected Ugandan Adults: Relationship to CD4 T Cell Count, Viral Load and Humoral Immune Responses. <i>PLoS ONE</i> , 2011, 6, e22653.	2.5	6
68	HIV-1 Viral Subtype Differences in the Rate of CD4+ T-Cell Decline Among HIV Seroincident Antiretroviral Naive Persons in Rakai District, Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, 180-184.	2.1	90
69	High-Throughput High-Resolution Class I HLA Genotyping in East Africa. <i>PLoS ONE</i> , 2010, 5, e10751.	2.5	10
70	Quality Monitoring of HIV-1-Infected and Uninfected Peripheral Blood Mononuclear Cell Samples in a Resource-Limited Setting. <i>Vaccine Journal</i> , 2010, 17, 910-918.	3.1	20
71	A Phase 1/2 Study of a Multiclade HIV-1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV-Uninfected East Africans (RV 172). <i>Journal of Infectious Diseases</i> , 2010, 201, 600-607.	4.0	100
72	Elevated Natural Killer Cell Activity Despite Altered Functional and Phenotypic Profile in Ugandans With HIV-1 Clade A or Clade D Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 380-389.	2.1	46

#	ARTICLE	IF	CITATIONS
73	Relatively Low HIV Infection Rates in Rural Uganda, but with High Potential for a Rise: A Cohort Study in Kayunga District, Uganda. <i>PLoS ONE</i> , 2009, 4, e4145.	2.5	28
74	Effect of Human Immunodeficiency Virus Type 1 (HIV-1) Subtype on Disease Progression in Persons from Rakai, Uganda, with Incident HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2008, 197, 707-713.	4.0	230
75	Reference Intervals in Healthy Adult Ugandan Blood Donors and Their Impact on Conducting International Vaccine Trials. <i>PLoS ONE</i> , 2008, 3, e3919.	2.5	75
76	Large-Scale Human Immunodeficiency Virus Rapid Test Evaluation in a Low-Prevalence Ugandan Blood Bank Population. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3281-3285.	3.9	31
77	Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. <i>Vaccine</i> , 2007, 25, 7737-7742.	3.8	23
78	Higher HIV-1 Incidence and Genetic Complexity Along Main Roads in Rakai District, Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, 440-445.	2.1	44
79	CD40 Ligand Enhances Dengue Viral Infection of Dendritic Cells: A Possible Mechanism for T Cell-Mediated Immunopathology. <i>Journal of Immunology</i> , 2006, 177, 6497-6503.	0.8	32
80	DC-SIGN (CD209) Mediates Dengue Virus Infection of Human Dendritic Cells. <i>Journal of Experimental Medicine</i> , 2003, 197, 823-829.	8.5	766
81	Preparation of Clinical-Grade Recombinant Canarypox-Human Immunodeficiency Virus Vaccine-Loaded Human Dendritic Cells. <i>Journal of Infectious Diseases</i> , 2002, 186, 1242-1252.	4.0	26
82	Human Dendritic Cells as Targets of Dengue Virus Infection. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2001, 6, 219-224.	0.8	149
83	Susceptibility to HIV-1 Acquisition linked to Malaria Exposure: A Case-control Study. <i>Clinical Infectious Diseases</i> , 0, , .	5.8	0